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Abstract
While circulating levels of soluble Intercellular Adhesion Molecule 1 (sICAM-1) have been associated with diverse conditions
including myocardial infarction, stroke, malaria, and diabetes, comprehensive analysis of the common genetic determinants
of sICAM-1 is not available. In a genome-wide association study conducted among 6,578 participants in the Women’s
Genome Health Study, we find that three SNPs at the ICAM1 (19p13.2) locus (rs1799969, rs5498 and rs281437) are non-
redundantly associated with plasma sICAM-1 concentrations at a genome-wide significance level (P,5610
28), thus
extending prior results from linkage and candidate gene studies. We also find that a single SNP (rs507666, P=5.1610
229)a t
the ABO (9q34.2) locus is highly correlated with sICAM-1 concentrations. The novel association at the ABO locus provides
evidence for a previously unknown regulatory role of histo-blood group antigens in inflammatory adhesion processes.
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Introduction
ICAM-1 is a member of the immunoglobulin superfamily of
adhesion receptors and consists of 5 immunoglobulin-like extracel-
lular domains, a transmembrane domain and a short cytoplasmic
domain. ICAM-1, present on endothelial cells, serves as a receptor
for the leukocyte integrins LFA-1 (lymphocyte function-associated
antigen-1) and Mac-1 (CD11b/CD18), facilitating leukocyte
adhesion and migration across the endothelium [1]. A soluble form
of ICAM-1 (sICAM-1) is found in plasma and consists of the extra-
cellular domains of ICAM-1. Although the process leading to the
formation of sICAM-1 is not entirely clear, sICAM-1 is thought to
be shed from the cell membrane via proteolytic cleavage of ICAM-
1. Because sICAM-1 binds to LFA-1, it is capable of inhibiting
lymphocyte attachment to endothelial cells [2]. Furthermore,
sICAM-1 has been shown to bind human rhinoviruses, the etiologic
agent of 40–50% of common colds, and to inhibit rhinovirus
infection in vitro [3]. Likewise, a circulating fragment of sICAM-1
binds to erythrocytes infected with Plasmodium falciparum, the
etiologic agent of malaria [4] (MIM 611162). Finally, plasma
concentration of sICAM-1 has been shown to provide unique
predictive value for the risk of myocardial infarction (MIM 608446),
ischemic stroke (MIM 601367), peripheral arterial disease (MIM
606787) and noninsulin-dependent diabetes mellitus (MIM 125853)
in epidemiological studies [5–7].
Despite relatively high heritability estimates (from 0.34 to 0.59)
[8,9] for sICAM-1, few genetic variants are known to influence its
concentrations. Two recent linkage studies have shown evidence
for genetic association at the ICAM1 (GeneID 3383) locus
(19p13.3-p13.2) [8,9] and two candidate SNPs within the
extracellular domains of ICAM-1 itself, G241R (rs1799969) and
K469E (rs5498), have been correlated with circulating sICAM-1
levels [10,11]. By contrast, a recent genome wide association study
(GWAS) from the Framingham investigators involving 1006
participants and 70,987 SNPs revealed no association reaching a
genome-wide level of significance, including the ICAM1 locus
itself, although this study had no genetic marker within 60 kb of
the gene [12]. To more comprehensively explore this issue, we
performed a larger GWAS, evaluating 336,108 SNPs in 6,578
apparently healthy women.
Methods
Study Sample and sICAM-1 Measurements
All participants in this study were part of the Women’s Genome
Health Study (WGHS) [13]. Briefly, participants in the WGHS
include American women from the Women’s Health Study (WHS)
with no prior history of cardiovascular disease, diabetes, cancer, or
other major chronic illness who also provided a baseline blood
sample at the time of study enrollment. The WHS is a recently
PLoS Genetics | www.plosgenetics.org 1 July 2008 | Volume 4 | Issue 7 | e1000118completed 262 randomized clinical trial of low-dose aspirin and
vitamin E in the primary prevention of cardiovascular disease and
cancer. For all WGHS participants, EDTA anticoagulated plasma
samples were collected at baseline and stored in vapor phase liquid
nitrogen (2170uC). Circulating plasma sICAM-1 concentrations
were determined using a commercial ELISA assay (R&D Systems,
Minneapolis, Minn.); the assay used is known not to recognize the
K56M (rs5491) variant of ICAM-1 [14] and the 22 carriers of this
mutation were therefore excluded from further analysis. This study
has been approved by the institutional review board of the
Brigham and Women’s Hospital. Additional clinical characteristics
of these subsets are provided in Table S1.
Genotyping
Genotyping was performed in two stages, a first sample being
used to discover new associated loci and the second sample being
used to validate them by replication. These two samples were
genotyped independently of one another in two batches. The first
(WGHS-1) and second (WGHS-2) batches included 4,925 and
2,056 self-reported Caucasian WGHS participants, respectively.
No related individuals were detected when tested with an identity
by state analysis [15].
Samples were genotyped with the Infinium II technology from
Illumina. Either the HumanHap300 Duo-Plus chip or the
combination of the HumanHap300 Duo and I-Select chips was
used. In either case, the custom content was identical and
consisted of candidate SNPs chosen without regard to allele
frequency to increase coverage of genetic variation with impact on
biological function including metabolism, inflammation or cardio-
vascular diseases. Genotyping at 318,237 HumanHap300 Duo
SNPs and 45,571 custom content SNPs was attempted, for a total
of 363,808 SNPs. Genetic context for all annotations are derived
from human genome build 36.1 and dbSNP build 126.
SNPs with call rates ,90% were excluded from further analysis.
Likewise, all samples with percentage of missing genotypes higher
than 2% were removed. Among retained samples, SNPs were
further evaluated for deviation from Hardy-Weinberg equilibrium
using an exact method [16] and were excluded when the P-value
was lower than 10
26. Samples were further validated by
comparison of genotypes at 44 SNPs that had been previously
ascertained using alternative technologies. SNPs with minor allele
frequency .1% in Caucasians were used for analysis. After quality
control, 307,748 HumanHap300 Duo SNPs and 28,360 custom
content SNPs were left, for a total of 336,108 SNPs. From the
initial 4925 WGHS-1 and 2056 WGHS-2 individuals genotyped,
4582 WGHS-1 individuals and 2014 WGHS-2 individuals were
kept for further analysis.
Population Stratification
Because population stratification can resultininflated type I error,
a principal component analysis using 1443 ancestry informative
SNPs was performed using PLINK [17] in order to confirm self-
reported ancestry. Briefly, these SNPs were chosen based on Fst
.0.4 in HapMap populations (YRB, CEU, CHB+JPT) and inter-
SNP distance at least 500 kb in order to minimize linkage
disequilibrium. Different ethnic groups were clearly distinguished
with the two first components. Out of 4582 WGHS-1 and 2014
WGHS-2 self-identified Caucasians, 12 and 6 were removed from
analysis because they did not cluster with other Caucasians, leaving
4570 (WGHS-1) and 2008 (WGHS-2) participants for analysis,
respectively. Two more analyses were undertaken to rule out the
possibility that residual stratification within Caucasians was
responsible for the associations observed. First, association analysis
wasdone withcorrectionbygenomiccontrol.Thismethod estimates
the average effect of population substructure in the sample (based on
median T values) and accordingly corrects the test statistics [18].
Second, a principal component analysis [19] was performed in
Caucasians (only) using 124,931 SNPs chosen to have pair-wise
linkage disequilibrium lower than r
2=0.4. The first three compo-
nents were then used as covariates in the association analysis. As
adjustment by these covariates did not change the conclusions, we
present analysis among the WGHS-1 and WGHS-2 Caucasian
participants without further correction for sub-Caucasian ancestry
unless stated otherwise.
Association Analysis
To identify common genetic variants influencing sICAM-1 levels,
we first attempted to discover which loci significantly contributed to
sICAM-1 concentrations in WGHS-1. Plasma concentrations of
sICAM-1 were adjusted for age, smoking, menopause and body
mass index using a linear regression model inR to reduce the impact
of clinical covariates on sICAM-1 variance. The adjusted sICAM-1
values were then tested for association with SNP genotypes by linear
regression inPLINK[17], assuming an additive contribution of each
minor allele. A conservative P-value cut-off of 5610
28 was used to
correct for the roughly 1,000,000 independent statistical tests
thought to correspond to all the common genetic variation of the
human genome [20]. Replication of genome-wide significant
associations was performed on adjusted sICAM-1 values from the
replication sample (WGHS-2), using a Bonferroni correction to
account for multiple hypothesis testing.
Model Selection Algorithm
To further define the extent of genetic associations, a forward
selection linear multiple regression model was used at the
previously identified loci. Briefly, all genotyped SNPs within
100 kb of the most significantly associated SNP at each replicated
locus and passing quality control requirements were tested for
possible incorporation into a multiple regression model. In
stepwise fashion, a SNP was added to the model if its multiple
regression P-value was less than 10
24 (to account for all the SNPs
being considered) and if it had the smallest P-value among all the
SNPs not yet included in the model. This analysis was done on
WGHS-1 individuals using adjusted sICAM-1 values.
We then proceeded to validate our multiple regression model in
WGHS-2 samples. Using only the SNPs previously selected in
WGHS-1, we added them in a multiple regression model in the
same order as they were chosen in WGHS-1. We considered the
model validated if each time a SNP was included in the model, its
Author Summary
Soluble Intercellular Adhesion Molecule 1 (sICAM-1) is an
inflammatory marker that has been associated with several
common diseases such as diabetes, heart disease, stroke,
and malaria. While it is known that blood concentrations of
sICAM-1 are at least partially genetically determined, our
current knowledge of which genes mediate this effect is
limited. Taking advantage of new technologies allowing us
to interrogate genetic variation on a whole genome basis,
we found that a variation in the ABO gene is an important
determinant of sICAM-1 blood concentrations. Since the
ABO gene is responsible for the ABO blood groups, this
discovery sheds light on a new role for blood groups and
offers novel mechanisms to explain the association
between sICAM-1 blood concentrations and various
common diseases.
Genetic Determinants of sICAM-1
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testing) and the direction of effect consistent.
Analytical Interference Assay
Plasma from A blood group individuals was mixed 1:1 or 1:2 with
a monoclonal anti-A antibody (Ortho-Clinical Diagnostics, Roche-
ster NY), and allowed to incubate 10 minutes or 60 minutes at room
temperature, or 60 minutes or 12 hours at 4uCb e f o r ea s s a y i n g
sICAM-1 levelsbythe standardtechnique.Toexclude thepossibility
that the antibody itself interfered with the assay, the same procedure
was repeated with plasma from O blood group individuals. Finally,
plasma from O group individuals, which is expected to contain both
anti-A and anti-B polyclonal antibodies, was mixed with plasma
from A groupindividualsin1:1 ratio, againwith incubation as above
and measurement of sICAM-1 levels.
Results/Discussion
As shown in Table 1, 19 SNPs passed our stringent genome-
wide significance threshold when tested in WGHS-1 individuals,
clustering within two loci in the vicinity of the ICAM1 (19p13.2)
and ABO (GeneID 28) (9q34.2) genes (Figure 1). The replication
threshold in WGHS-2 was conservatively set at a 2-sided P-value
of 0.002, applying a Bonferroni correction to account for 19 tests.
Using this cutoff, we were able to replicate 17 of the 19 associated
SNPs, including SNPs at both the ICAM1 and ABO loci. Only
rs2116941 (19p13.2) and rs7256672 (19p13.2) did not replicate
using this standard. Nevertheless, each of these SNPs had a P-
value lower than 10
29 when tested on the combined sample (i.e.
WGHS-1 and WGHS-2 pooled together). Among the replicated
SNPs, only rs7258015 (19p13.2) deviated from Hardy-Weinberg
equilibrium (p=0.00007), but visual inspection of the raw
genotyping signal for this SNP did not reveal any obvious artifact.
Major and minor alleles are shown in Table S2.
We then applied our model selection algorithm in WGHS-1
individuals (see Methods) using 54 SNPs at 19p13.2 (ICAM1
locus) and 68 SNPs at 9q34.2 (ABO locus). As can be seen in
Table 2, 3 out of 54 SNPs at 19p13.2 were selected by our
algorithm and 1 out 68 SNPs at 9q34.2 was selected. All four SNPs
selected in WGHS-1 were validated in WGHS-2. Pairwise linkage
disequilibrium between these SNPs was low. For instance, r
2 was
lower than 0.35 between ICAM1 SNPs while it was lower than
0.002 between the ABO SNP rs507666 and the ICAM1 SNPs.
Among these SNPs, there was no strong evidence for non-additive
effects of the minor allele as judged by lack of significance for a
likelihood ratio test comparing the additive regression model to an
alternative genotype model with an additional degree of freedom.
Interestingly, one of the four selected SNPs (rs281437) was non-
significant in univariate analysis, illustrating that its inclusion in the
model and significant association are conditional on the genotypes
at rs5498 and rs281437. No gene-gene interaction was observed
between ICAM1 and ABO SNPs. The 3 SNPs at 19q13.2
(ICAM1) collectively explained 6.9% of the total variance in
sICAM-1 concentrations (pooling WGHS-1 and WGHS-2
together), whereas the ABO SNP rs507666 explained 1.5%. In
comparison, clinical covariates accounted for 18.8% of the
variance (Table 3), and together the candidate loci and the
clinical variables accounted for 27.3% of total variance. It should
be noted that the estimated effect sizes of the ICAM1 and ABO
loci are minimums since the genotyped variants might not be the
actual functional variants.
The 3 SNPs at the 19p13.2 (ICAM1) locus selected by our
algorithm were also used in haplotype analysis using WHAP [21],
as implemented in PLINK [17] (Table 4). The estimate of the
proportion of variance attributable to haplotypes, as well as their
regression coefficients, is consistent with the linear model of these
same SNPs, reinforcing the adequacy of a strictly additive model
to explain the association.
The ABO histo-blood group antigen is the most important
blood group system in transfusion medicine. Using data from
Seattle SNPs (http://pga.mbt.washington.edu) as well as from the
Blood Group Antigen Mutation Database (www.ncbi.nlm.nih.
gov), it can be demonstrated that rs507666 is a perfect surrogate
for type A1 histo-blood group antigen. Moreover, using rs687289
as a marker for the O allele, rs8176746 for the B allele and
rs8176704 for the A2 allele, complete blood group antigen
phenotype can be re-constructed by haplotype analysis (no
serotype data is available in WGHS). Imputed haplotypes perfectly
fitted the pattern expected from the literature and their association
with sICAM-1 is shown in Tables 5 and 6. The A1 allele is
associated with the lowest sICAM-1 concentrations while the A2
allele is associated with low concentrations, intermediate between
the A1 and O allele. In comparison, the B allele is associated with
slightly higher concentrations than the O allele.
Because ABO histo-blood group antigens are known to vary in
frequency among Caucasian sub-populations, we sought to
investigate the potential effect of population stratification on the
observed association even though adjustment of sICAM-1 values for
the top ten components of our principal component analysis did not
change our conclusions (see Methods). Visual inspection of the
clustering pattern from the top two components confirmed a match
with previously published work of sub-Caucasian stratification [22]
(data not shown). Since these two components were reproducibly
shown to correspond to a Northwest-Southeast European gradient
[22] and the A1 allele follows such a gradient [23], we hypothesized
that they would be tightly linked to A1 allele frequencies. Indeed, the
second component showed evidence of association with A1 allelic
frequencies (p=2.5610
26), while the first component was only
weakly associated (p=0.08). Nevertheless, neither the first nor
second component was very tightly linked to sICAM-1 values
(p=0.69 and 0.0006 respectively with corresponding R
2 of
3.8610
25 and 0.0019), implying that stratification has no major
effect on the sICAM-1 association. Furthermore, the weak
association with the second component could be partially explained
by the correlation with A1 alleles, with corrected P-value of 0.004
and R
2 of 0.0013. Adjustment of sICAM-1 values for the first and
second components did not substantially change the association
between the A1 allele and sICAM-1 (unadjusted p=5.1610
229 and
adjusted p=5.5610
228), demonstrating that stratification on a
Northwest-Southeast European axis is not responsible for the
association. We conclude that the data does not support the
hypothesis that Northwest-Southeast sub-Caucasian stratification is
responsible for the association of ABO variants with sICAM-1
concentrations since the A1 allele varies in frequency according to a
Northwest-Southeast European axis while the slight variation in
sICAM-1 among this same axis is at least partially dependent on the
A1 allele. Indeed, there is no evidence in the literature that mean
sICAM-1 concentrations vary at all among Caucasian sub-
populations, and this lack of evidence is supported by an overall
R
2 of 0.005 (P-value of 0.0007) for the association between sICAM-1
concentrations and the top 10 principal components.
The Secretor phenotype (as defined by rs601338 on
chromosome 19q13.33) and the Lewis antigen phenotype (as
defined by rs812936 on chromosome 19p13.3) are additional
important members of the histo-blood group antigen system.
These were therefore tested for association with sICAM-1 levels as
well as for interaction with rs507666. No significant effect was
observed.
Genetic Determinants of sICAM-1
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Genetic Determinants of sICAM-1
PLoS Genetics | www.plosgenetics.org 4 July 2008 | Volume 4 | Issue 7 | e1000118Although the sICAM-1 molecule itself is not known to bear the
ABO histo-blood group antigen, this possibility could not be ruled
out, especially given its extensive glycosylation [24,25]. We
therefore sought to exclude the remote chance that the association
between A histo-blood group antigen and lower sICAM-1 values
was the consequence of a lower affinity of the antibodies used in
the sICAM-1 assay for sICAM-1 carrying the A antigen. In other
words, if sICAM-1 does carry ABO histo-blood group antigen,
then the allelic composition at the ABO locus could dictate the
glycosylation status of the sICAM-1 molecule and possibly
interfere with the immunoassay used. While there is no evidence
that the two plasma proteins known to contain ABO histo-blood
group antigen (von Willebrand factor and alpha 2-macroglobulin)
[26] suffer from such analytical interference, immunoassays are
potentially susceptible to differential glycosylation of their target
protein [27]. We thus hypothesized that blocking the A antigen
sites with either polyclonal or monoclonal antibodies would result
in spuriously low sICAM-1 values if sICAM-1 does indeed carry
ABO histo-blood group antigen and if the A antigen is located in
the vicinity of one of the two antibody binding sites used by the
immunoassay. No differential effects of the mixing procedures (see
Methods) were observed suggesting that the A blood group antigen
was not interfering with measurement of sICAM-1 levels. We
therefore conclude that the genetic association of the ABO variant
is not due to analytic interference. However, we can not exclude
that sICAM-1 bears the ABO histo-blood group antigen.
Finally, we sought to assess the presence of other associations
that did not pass our stringent genome-wide P-value cut-off. We
Figure 1. Genetic Context of Genome-Wide Significant Associations. Genomic context for each of two loci with genome-wide association
with sICAM-1 levels. The ICAM1 locus (19p13.2) is shown in Figure 1-A and the ABO locus (9q34.2) in Figure 1-B. Upper panel: Genes from RefSeq
release 25. Only one isoform is shown when multiple splicing variants are known. Middle Panel: SNPs are shown according to their physical location
and P-values (red dots). Also shown is the genetic distance in cM from the lowest P-value SNP (light grey line) along with the position of
recombination hotspots (light grey vertical bars). Recombination rates and hotspots are based on HapMap data, as described by McVean et al.[53]
and Winckler et al. [54]. Lower panel: Pair wise linkage disequilibrium (D9 and R
2) between SNPs based on WGHS data.
doi:10.1371/journal.pgen.1000118.g001
Table 2. Multiple Linear Regression Statistics of SNPs Retained by the Forward Model Selection Algorithm.
Locus SNP Nearest Gene Function MAF
a HW
b WGHS-1
c WGHS-2
c Combined
c
Beta P-Value Beta P-Value Beta P-Value
19p13.2 rs1799969 ICAM1 NS
d 0.12 0.34 241.2 ,2.0E-16 249.3 ,2.0E-16 243.5 ,2.0E-16
rs5498 ICAM1 NS
d 0.43 0.15 30.4 ,2.0E-16 28.3 ,2.0E-16 29.7 ,2.0E-16
rs281437 ICAM1 39 UTR
e 0.30 0.47 11.2 1.3E-08 7.9 5.1E-03 10.1 3.2E-10
9q34.2 rs507666 ABO intron 0.20 0.42 216.8 ,2.0E-16 216.8 1.9E-10 216.7 ,2.0E-16
aMAF: Minor allele frequency based on the combined samples.
bHW: Deviation from Hardy-Weinberg equilibrium P-value based on the combined samples.
cAll analyses were performed using adjusted sICAM1 values (see text for details). Beta coefficients and P-values were derived form a multiple linear model that included
all 4 SNPs.
dNS: Non-Synonymous Coding SNP.
e39 UTR: 39 Untranslated Region.
doi:10.1371/journal.pgen.1000118.t002
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PLoS Genetics | www.plosgenetics.org 5 July 2008 | Volume 4 | Issue 7 | e1000118therefore repeated the whole-genome association analysis on the
combined sample (i.e. WGHS-1 and WGHS-2 pooled together).
While no new locus was associated at a genome-wide level,
rs9889486 had the lowest p-value (outside of 9q34.2 and19p13.2;
p=3.2610
26) with a false discovery rate [28] of 0.03. This SNP is
intronic to CCDC46 (GeneID 201134) (17q24.1), a gene whose
function is not well characterized. Among other low p-value SNPs,
we note rs1049728 (p=1.3610
25) with a false discovery rate of
0.08 and the 51
st most strongly associated SNP overall. This SNP
is located in the 39 untranslated region of RELA (GeneID 5970)
(11q13.1), which is part of the NFKB signaling complex, arguably
the most important known regulator of ICAM1 expression [29].
The non-synonymous coding ICAM1 SNPs rs1799969 (G241R)
and rs5498 (K469E) were previously described as being associated
with sICAM-1 levels[10,11] whereas the association involving
rs281437 is unreported. The later SNP is in the 39 untranslated
region of ICAM-1. Of interest, the minor allele of rs1799969
(arginine) is correlated with lower sICAM-1 and has been
associated with lower risk of type I diabetes[30], while the minor
allele of rs5498 (glutamic acid) is correlated with higher sICAM-1
levels and has been associated with lower risk of asthma [11]
(MIM 600807), inflammatory bowel disease [31] (MIM 266600)
and type I diabetes [32] (MIM 222100). Furthermore, it has been
demonstrated in vitro that this SNP affects ICAM-1 mRNA splicing
pattern and apoptosis in human peripheral blood mononuclear
cells [33]. It is also noteworthy that sICAM-1 has been shown to
inhibit insulitis and onset of autoimmune diabetes in a mouse
model of type I diabetes [34] whereas ICAM1 itself was proven to
be crucial to the priming of T cells against beta cells [35].
The most striking result of this report is the association between
sICAM-1 levelsand rs507666,a SNP intronictotheABOgene.The
ABO gene encodes glycosyltransferase enzymes which transfer
specificsugarresiduestoaprecursorsubstance,theHantigen.There
are three major alleles at the ABO locus: A, B and O. Variation at
the ABO locus is remarkable in that these alleles encode enzymes
with different specificities as well as activities. The A allele encodes
the enzyme alpha1R3 N-acetylgalactosamyl-transferase which
forms the A antigen from the H antigen. The A allele (as well as
the B and O alleles) is itself heterogeneous and comprises several
subgroups, of which A1 and A2 are the most important. As
compared to A1, the A2 allele has 30–50 fold less A transferase
activity [36]. The B allele encodes the enzyme alpha1R3
galactosyltransferase which forms the B antigen from the H antigen.
The O allele does not produce an active enzyme [37]. Consistent
Table 3. Partition of sICAM-1 Variance According to Genetic
and Clinical Variables.
Category Variable Variable R
2 Category R
2
Clinical Covariates Age 0.012 0.188
Body Mass Index 0.035
Menopause Status 0.006
Smoking 0.135
9q34.2 (ABO) Locus rs507666 0.015 0.015
19p13.2 (ICAM1) Locus rs1799969 0.026 0.069
rs5498 0.039
rs281437 0.005
TOTAL 0.273
doi:10.1371/journal.pgen.1000118.t003
Table 4. Haplotype Analysis of rs1799969, rs5498 and
rs281437 (19p13.2; ICAM1 Locus).
Haplotype Frequency Beta P-Value
rs1799969 rs5498 rs281437
A G G 0.12 243.91 1.7E-95
G A G 0.27 230.16 3.0E-78
G A A 0.30 219.98 5.3E-37
G G G 0.32 Reference -
Omnibus (3 df) p-value=1.0E-124. WGHS-1 and WGHS-2 were combined for
this analysis.
doi:10.1371/journal.pgen.1000118.t004
Table 5. Association of sICAM-1 Concentrations (mmol/L) with Histo-Blood Group Antigen Alleles (9q34.2; ABO Locus).
Allele Genotype Frequency Beta
rs8176746 rs8176704 rs687289 rs507666
A 1 C G AA0 . 2 0 214.3
A2 C A A G 0.07 22.2
B A G A G 0.08 4.7
O C G G G 0.66 3.9
Omnibus (3 df) p-value=2.0E-28. WGHS-1 and WGHS-2 were combined for this analysis.
doi:10.1371/journal.pgen.1000118.t005
Table 6. Mean (SD) Level of sICAM-1 (mmol/L) According to
Predicted ABO Alleles.
First Allele
A1 A2 O B
Second Allele A1 326 (71)
N=268
332 (71)
N=185
338 (77)
N=1656
352 (89)
N=182
A2 - 346 (55)
N=33
352 (80)
N=537
366 (91)
N=56
O - - 358 (81)
N=2859
356 (80)
N=592
B - - - 342 (79)
N=51
WGHS-1 and WGHS-2 were combined for this analysis. Mean (SD) values were
derived from unadjusted sICAM-1 concentrations.
doi:10.1371/journal.pgen.1000118.t006
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PLoS Genetics | www.plosgenetics.org 6 July 2008 | Volume 4 | Issue 7 | e1000118with the A antigen being associated with lower sICAM-1
concentrations and with the A1 allele having 30–50 fold more A
transferase activity than the A2 allele, the A1 allele is associated with
the lowest sICAM-1 concentrations while the A2 allele is associated
with low concentrations as well, but still higher than the A1 allele
(Table 5). Although we excluded the possibility of an analytical
interference to explain the association, the exact mechanism linking
histo-blood group antigen to sICAM-1 concentrations remains
elusive. Among the different hypotheses, it remains possible that
sICAM-1 bears the A antigen, a modification that might increase its
clearance by increasing its affinity for its receptor(s) and/or decrease
its secretion, perhaps by decreasing its affinity for the protease(s)
producing sICAM-1 from membrane-bound ICAM1. Alternatively,
lower sICAM-1 concentrations might be the result of the presence of
the A antigen on its receptor(s) and/or protease(s).
ABO histo-blood group phenotype has been linked to a plethora
of diseases, including infectious diseases, cancers and vascular
diseases [38]. Particularly interesting is the association of non-O
histo-blood groups — and group A in particular [39,40] — with a
higher risk of myocardial infarction, peripheral vascular disease,
strokes and venous thromboembolism [41] (MIM 188050). While
this phenomenon is partially explained by higher concentrations of
the coagulation factors vonWillebrand and VIII (presumably
because of decreased clearance) [42], the exact mechanism is not
entirely understood. Underlining the complex nature of the
biological processes involved, the A1 group (rs507666) is associated
with lower levels of sICAM-1, a (positive) predictor of vascular
diseases in epidemiological studies [5,6,43–46]. Among potential
explanations as to this apparent disparity, it is possible that
decreased sICAM-1 leads to increased adhesion of leukocytes on
endothelial surface and therefore increased vascular inflammation,
an important component of atherosclerosis [47]. Moreover,
because group A individuals have been shown to have higher
blood cholesterol [48] and coagulability [42], the decrease in
sICAM-1 seen in these individuals could be offset by the increased
susceptibility to vascular diseases conferred by these risk factors,
even if sICAM-1 mechanistically causes these diseases. Alterna-
tively, sICAM-1 might merely be a marker of increased
inflammation and coagulation [49], both risk factors for vascular
diseases. Also of special interest, group A antigen carriers have
been recognized as having a higher risk of suffering from severe
malaria when infected by Plasmodium falciparum [50]. Plamodium
infected erythrocytes express a receptor (PfEMP-1) that binds
specifically to cell-surface group A and B antigen as well as ICAM-
1 [51], a major step in the sequestration of infected erythrocytes
leading to the clinical complications of severe and cerebral
malaria. The lower concentrations of sICAM-1 found in A1 group
carriers could therefore be hypothesized to contribute to this
higher risk either directly, if sICAM-1 can inhibit the sequestration
process, or indirectly, if sICAM-1 levels reflect differences in the
processing of the ICAM1 receptor itself.
Several limitations warrant discussion. First, this study was
conducted in Caucasian women. It is therefore difficult to
generalize our results to other ethnicities or to men. Second,
effect estimates derived from this study might be higher than in
other populations as these are initial findings and because of the
winner’s curse [52]. Third, although we were able to rule out a
technical artifact as the cause of our results, no mechanistic link is
identified to explain the association between ABO histo-blood
groups and sICAM-1. In particular, one pending question is
whether or not ICAM-1 bears any ABO antigen at all.
In this report, we demonstrate that sICAM-1 concentrations are
associated with genetic variation at the ABO and ICAM1 loci in
women. To our knowledge, this represents the first published genetic
evidence that ABO may have a regulatory role on an inflammatory
mediator, a finding with potential implication on a diverse array of
immune-mediated disorders. Especially interesting is the fact that
both ABO and ICAM1 have been previously related to vascular
disease and malaria, two major causes of mortality and morbidity
worldwide. The current study indicates a genetic link between histo-
blood group antigen and inflammatory adhesion processes,
providing the basis for physiological studies of this interaction.
Supporting Information
Table S1 Clinical Characteristics of the Samples Used.
Found at: doi:10.1371/journal.pgen.1000118.s001 (0.04 MB
DOC)
Table S2 Major and Minor Alleles.
Found at: doi:10.1371/journal.pgen.1000118.s002 (0.04 MB
DOC)
Acknowledgments
We thank the study research team and the women who have participated
in the study. We also thank Lynda Rose for her review of the manuscript
and helpful comments.
Author Contributions
Conceived and designed the experiments: GP DC MK RZ NR JM PR.
Performed the experiments: MK RZ NR SB. Analyzed the data: GP DC.
Wrote the paper: GP DC.
References
1. van de Stolpe A, van der Saag PT (1996) Intercellular adhesion molecule-1.
J Mol Med 74: 13–33.
2. Rieckmann P, Michel U, Albrecht M, Bruck W, Wockel L, et al. (1995) Soluble
forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte
attachment to cerebral endothelial cells. J Neuroimmunol 60: 9–15.
3. Marlin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber W, et al.
(1990) A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus
infection. Nature 344: 70–72.
4. Ockenhouse CF, Betageri R, Springer TA, Staunton DE (1992) Plasmodium
falciparum-infected erythrocytes bind ICAM-1 at a site distinct from LFA-1,
Mac-1, and human rhinovirus. Cell 68: 63–69.
5. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J (1998)
Plasma concentration of soluble intercellular adhesion molecule 1 and risks
of future myocardial infarction in apparently healthy men. Lancet 351: 88–92.
6. Pradhan AD, Rifai N, Ridker PM (2002) Soluble intercellular adhesion
molecule-1, soluble vascular adhesion molecule-1, and the development of
symptomatic peripheral arterial disease in men. Circulation 106: 820–825.
7. Song Y, Manson JE, Tinker L, Rifai N, Cook NR, et al. (2007) Circulating levels
of endothelial adhesion molecules and risk of diabetes in an ethnically diverse
cohort of women. Diabetes 56: 1898–1904.
8. Bielinski SJ, Pankow JS, Foster CL, Miller MB, Hopkins PN, et al. (2007)
Circulating soluble ICAM-1 levels shows linkage to ICAM gene cluster region
on chromosome 19: The NHLBI Family Heart Study follow-up examination.
Atherosclerosis.
9. Kent JW Jr, Mahaney MC, Comuzzie AG, Goring HH, Almasy L, et al. (2007)
Quantitative trait locus on Chromosome 19 for circulating levels of intercellular
adhesion molecule-1 in Mexican Americans. Atherosclerosis 195: 367–373.
10. Ponthieux A, Lambert D, Herbeth B, Droesch S, Pfister M, et al. (2003)
Association between Gly241Arg ICAM-1 gene polymorphism and serum
sICAM-1 concentration in the Stanislas cohort. Eur J Hum Genet 11: 679–686.
11. Puthothu B, Krueger M, Bernhardt M, Heinzmann A (2006) ICAM1 amino-
acid variant K469E is associated with paediatric bronchial asthma and elevated
sICAM1 levels. Genes Immun 7: 322–326.
12. Benjamin EJ, Dupuis J, Larson MG, Lunetta KL, Booth SL, et al. (2007)
Genome-wide association with select biomarker traits in the Framingham Heart
Study. BMC Med Genet 8 Suppl 1: S11.
13. Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, et al. (2008) Rationale,
Design, and Methodology of the Women’s Genome Health Study: A Genome-
Wide Association Study of More Than 25 000 Initially Healthy American
Women. Clin Chem 54: 249–255.
Genetic Determinants of sICAM-1
PLoS Genetics | www.plosgenetics.org 7 July 2008 | Volume 4 | Issue 7 | e100011814. Register TC, Burdon KP, Lenchik L, Bowden DW, Hawkins GA, et al. (2004)
Variability of serum soluble intercellular adhesion molecule-1 measurements
attributable to a common polymorphism. Clin Chem 50: 2185–2187.
15. Serre D, Montpetit A, Pare G, Engert JC, Yusuf S, et al. (2008) Correction of
population stratification in large multi-ethnic association studies. PLoS ONE 3:
e1382.
16. Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy-
Weinberg equilibrium. Am J Hum Genet 76: 887–893.
17. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
18. Devlin B, Roeder K (1999) Genomic control for association studies. Biometrics
55: 997–1004.
19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006)
Principal components analysis corrects for stratification in genome-wide
association studies. Nat Genet 38: 904–909.
20. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second
generation human haplotype map of over 3.1 million SNPs. Nature 449:
851–861.
21. Purcell S, Daly MJ, Sham PC (2007) WHAP: haplotype-based association
analysis. Bioinformatics 23: 255–256.
22. Price AL, Butler J, Patterson N, Capelli C, Pascali VL, et al. (2008) Discerning
the ancestry of European Americans in genetic association studies. PLoS Genet
4: e236.
23. Cavalli-Sforza LL, Menozzi P, Piazza A (1994) The History and Geography of
Human Genes. Princeton: Princeton University Press. 541 p.
24. Diamond MS, Staunton DE, Marlin SD, Springer TA (1991) Binding of the
integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of
ICAM-1 (CD54) and its regulation by glycosylation. Cell 65: 961–971.
25. Otto VI, Schurpf T, Folkers G, Cummings RD (2004) Sialylated complex-type
N-glycans enhance the signaling activity of soluble intercellular adhesion
molecule-1 in mouse astrocytes. J Biol Chem 279: 35201–35209.
26. Matsui T, Fujimura Y, Nishida S, Titani K (1993) Human plasma alpha 2-
macroglobulin and von Willebrand factor possess covalently linked ABO(H)
blood group antigens in subjects with corresponding ABO phenotype. Blood 82:
663–668.
27. Helander A, Eriksson G, Stibler H, Jeppsson JO (2001) Interference of
transferrin isoform types with carbohydrate-deficient transferrin quantification
in the identification of alcohol abuse. Clin Chem 47: 1225–1233.
28. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A
Practical and Powerful Approach to Multiple Testing. Journal of the Royal
Statistical Society Series B (Methodological) 57: 289–300.
29. Ledebur HC, Parks TP (1995) Transcriptional regulation of the intercellular
adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells.
Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem
270: 933–943.
30. Nejentsev S, Guja C, McCormack R, Cooper J, Howson JM, et al. (2003)
Association of intercellular adhesion molecule-1 gene with type 1 diabetes.
Lancet 362: 1723–1724.
31. Matsuzawa J, Sugimura K, Matsuda Y, Takazoe M, Ishizuka K, et al. (2003)
Association between K469E allele of intercellular adhesion molecule 1 gene and
inflammatory bowel disease in a Japanese population. Gut 52: 75–78.
32. Ma J, Mollsten A, Prazny M, Falhammar H, Brismar K, et al. (2006) Genetic
influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymor-
phisms in development of Type 1 diabetes and diabetic nephropathy. Diabet
Med 23: 1093–1099.
33. Iwao M, Morisaki H, Morisaki T (2004) Single-nucleotide polymorphism
g.1548G . A (E469K) in human ICAM-1 gene affects mRNA splicing pattern
and TPA-induced apoptosis. Biochem Biophys Res Commun 317: 729–735.
34. Martin S, Heidenthal E, Schulte B, Rothe H, Kolb H (1998) Soluble forms of
intercellular adhesion molecule-1 inhibit insulitis and onset of autoimmune
diabetes. Diabetologia 41: 1298–1303.
35. Camacho SA, Heath WR, Carbone FR, Sarvetnick N, LeBon A, et al. (2001) A
key role for ICAM-1 in generating effector cells mediating inflammatory
responses. Nat Immunol 2: 523–529.
36. Yamamoto F, McNeill PD, Hakomori S (1992) Human histo-blood group A2
transferase coded by A2 allele, one of the A subtypes, is characterized by a single
base deletion in the coding sequence, which results in an additional domain at
the carboxyl terminal. Biochem Biophys Res Commun 187: 366–374.
37. Yip SP (2002) Sequence variation at the human ABO locus. Ann Hum Genet
66: 1–27.
38. Greenwell P (1997) Blood group antigens: molecules seeking a function?
Glycoconj J 14: 159–173.
39. Platt D, Muhlberg W, Kiehl L, Schmitt-Ruth R (1985) ABO blood group
system, age, sex, risk factors and cardiac infarction. Arch Gerontol Geriatr 4:
241–249.
40. Medalie JH, Levene C, Papier C, Goldbourt U, Dreyfuss F, et al. (1971) Blood
groups, myocardial infarction and angina pectoris among 10,000 adult males.
N Engl J Med 285: 1348–1353.
41. Wu O, Bayoumi N, Vickers MA, Clark P (2008) ABO(H) blood groups and
vascular disease: a systematic review and meta-analysis. J Thromb Haemost 6:
62–69.
42. Jenkins PV, O’Donnell JS (2006) ABO blood group determines plasma von
Willebrand factor levels: a biologic function after all? Transfusion 46:
1836–1844.
43. de Lemos JA, Hennekens CH, Ridker PM (2000) Plasma concentration of
soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk.
J Am Coll Cardiol 36: 423–426.
44. O’Malley T, Ludlam CA, Riemermsa RA, Fox KA (2001) Early increase in
levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk
factor for the acute coronary syndromes. Eur Heart J 22: 1226–1234.
45. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, et al. (2005) C-reactive
protein, interleukin-6, and soluble adhesion molecules as predictors of
progressive peripheral atherosclerosis in the general population: Edinburgh
Artery Study. Circulation 112: 976–983.
46. Albert MA, Glynn RJ, Buring JE, Ridker PM (2007) Differential effect of soluble
intercellular adhesion molecule-1 on the progression of atherosclerosis as
compared to arterial thrombosis: A prospective analysis of the Women’s Health
Study. Atherosclerosis.
47. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis.
Circulation 105: 1135–1143.
48. Sing CF, Orr JD (1976) Analysis of genetic and environmental sources of
variation in serum cholesterol in Tecumseh, Michigan. III. Identification of
genetic effects using 12 polymorphic genetic blood marker systems. Am J Hum
Genet 28: 453–464.
49. Clark P, Jordan F, Pearson C, Walker ID, Sattar N, et al. (2003) Intercellular
adhesion molecule-1 (ICAM-1) expression is upregulated by thrombin in human
monocytes and THP-1 cells in vitro and in pregnant subjects in vivo. Thromb
Haemost 89: 1043–1051.
50. Cserti CM, Dzik WH (2007) The ABO blood group system and Plasmodium
falciparum malaria. Blood 110: 2250–2258.
51. Smith JD, Craig AG, Kriek N, Hudson-Taylor D, Kyes S, et al. (2000)
Identification of a Plasmodium falciparum intercellular adhesion molecule-1
binding domain: a parasite adhesion trait implicated in cerebral malaria. Proc
Natl Acad Sci U S A 97: 1766–1771.
52. Zollner S, Pritchard JK (2007) Overcoming the winner’s curse: estimating
penetrance parameters from case-control data. Am J Hum Genet 80: 605–615.
53. McVean GA, Myers SR, Hunt S, Deloukas P, Bentley DR, et al. (2004) The
fine-scale structure of recombination rate variation in the human genome.
Science 304: 581–584.
54. Winckler W, Myers SR, Richter DJ, Onofrio RC, McDonald GJ, et al. (2005)
Comparison of fine-scale recombination rates in humans and chimpanzees.
Science 308: 107–111.
Genetic Determinants of sICAM-1
PLoS Genetics | www.plosgenetics.org 8 July 2008 | Volume 4 | Issue 7 | e1000118